Evidence map›Paper›PMID 42149268›Full record

ArticleJournal of neuro-oncology2026

Outcome of CyberKnife stereotactic radiosurgery for the brain metastases in patients with Li Fraumeni syndrome.

Muhammad Izhar, Yusuke S Hori, Ahed H Kattaa, Paul M Harary, Fred C Lam, Neeraj Kalra, Nirmeen Zagzoog, Armine Tayag, Louisa Ustrzynski, Sara C Emrich and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Muhammad IzharDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Yusuke S HoriDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA. yshori@stanford.edu.
Ahed H KattaaDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Paul M HararyDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Fred C LamDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Neeraj KalraDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Nirmeen ZagzoogDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Armine TayagDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Louisa UstrzynskiDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Sara C EmrichDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
David J ParkDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA. djpark@stanford.edu.
Steven D ChangDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA. sdchang@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLi-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome associated with germline TP53 mutations and an increased risk of radiation-induced malignancies, posing significant challenges in the management of brain metastases (BM). Data regarding the safety and efficacy of stereotactic radiosurgery (SRS) for BM in this population remain limited.

methodsWe performed a retrospective analysis of patients with LFS who underwent SRS for BM at our institution. Patient-level, lesion-level, and treatment-related data were collected. Outcomes assessed included local tumor control (LTC), overall survival (OS), distant progression-free survival (DPFS), radiographic response, and treatment-related adverse events.

resultsA total of 5 patients with 16 BM lesions were treated with SRS. The median age at treatment was 49 years (range, 37-65). Lesions were typically small (median diameter 6.1 mm) and predominantly supratentorial (87.5%). Most lesions (93.7%) were treated with single-fraction SRS with a median prescribed dose of 24 Gy. LTC was 100% at 3 months, 6 months, and the last follow-up. Median OS and DPFS were 11.03 months (95% CI, 9.53-12.54) and 7.5 months (95% CI, 7.3-7.7), with all deaths attributable to systemic disease rather than neurological causes. Importantly, no cases of radiation necrosis or radiation-induced secondary malignancies were observed during a median follow-up of 45 weeks.

conclusionsSRS demonstrated a short-term favorable local control and safety profile for the treatment of BM in patients with LFS. Given the tendency for lesions to be small and multifocal, along with the need to minimize radiation exposure, SRS represents a rational, focal treatment approach in this high-risk population. However, longer follow-up and prospective studies are needed to better define long-term safety, particularly regarding the risk of radiation-induced malignancies. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Brain NeoplasmsLi-Fraumeni SyndromeRadiosurgeryAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeBrain metastasesCyberKnifeGamma knifeLi Fraumeni syndromeRadiosurgery

Identifiers

PMID42149268

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.